With our corporate mission of “Contributing to Society through Healthcare,” we work proactively to stably provide high-quality medical devices and services for the benefit of patients and medical settings in over 160 countries, while also developing solutions to advance the practice of healthcare.
Today, various social conditions are causing a diversification of needs in healthcare. Terumo is responding to these changes by developing and providing devices and systems that enhance safety and efficiency while also improving patient comfort. Recognizing that the benefits of medical devices are realized only if they are used correctly, we further offer healthcare professionals from throughout the world training in the use of advanced medical devices and new treatment techniques.
To continue contributing to healthcare as the future unfolds, we are “rising to the challenge of innovation” throughout the Terumo Group.
We strive ceaselessly to nurture developmental technologies into added value for healthcare, bring revolutionary advances to the frontlines of healthcare, and ultimately make better medical care available to patients.
Dr. Shibasaburo Kitasato, one of the founders of Terumo, placed great importance on the spirit of innovation and challenge throughout his life. As the heirs to the spirit of Dr. Kitasato, we are committed to carrying the pursuit of new value into the future of healthcare.
Contact
300 Beach Road, #33-03
The Concourse Singapore 199555
TEL: +65-6-295-1792
FAX: + 65-6-294-2329
A roundup of some of the most important recent pharma news from the dynamic ASEAN region, including a big new investment from Novartis in its antibody plant in Singapore, the…
The latest pharma and healthcare news from APAC, including Celltrion’s plans to sell its Takeda portfolio to CBC; reforms to the South Korean national insurance system that may lead to…
The latest pharma news from Singapore, including J&J Innovation’s continued investment in Singapore; Evotec’s new Singaporean venture, 65LAB; BeiGene’s cancer drug approval in the country; Novo Nordisk’s acquisition of local…
The latest pharma and healthcare news from Southeast Asia, including the partnership between KPJ Healthcare and Samsung; Specialised Therapeutics’ immuno-oncology therapy; Singapore biotech CytoMed Therapeutics’ IPO, the Malaysian approval of…
The latest pharma and healthcare news from Southeast Asia, including the proposed healthcare programs of Thailand’s political parties for the upcoming election; Singapore’s approval of Pfizer’s 20-valent pneumococcal conjugate vaccine;…
The biggest pharma stories from Southeast Asia, including GSK’s new HPF manufacturing investment, license suspensions for Samco Farma and Ciubros Farma after Indonesia’s acute kidney injury crisis, Kalbe’s Aventis share…
MSD is set to inject an additional USD 500 million into its existing Singapore manufacturing operations with two new facilities to produce vaccines and biologics. One of the new plants…
On World Heart Day 2022 Iris Zemzoum of Novartis Asia Pacific, Middle East & Africa (APMA) outlines the devastating impact of cardiovascular disease (CVD) as well as Novartis’ multipronged approach…
Japanese giant Takeda has a new Head for APAC; Indian national Dr Mahender Nayak, previously the firm’s India, CIS, Middle East, Turkey & Africa (ICMEA) lead. Nayak will relocate to…
The latest healthcare and pharma news from Singapore, including the partnership between Boehringer Ingelheim and A*STAR for targeted cancer therapies, Amgen’s sponsorship of biotech incubator, NSG BioLabs, and Tessa Therapeutics’…
The latest pharma news from Southeast Asia, including the Singaporean Health Sciences Authority (HSA) being awarded the highest maturity level in the WHO’s classification of global regulatory authorities, as well…
Writing in the December edition of DIA’s Global Forum magazine, Agnes Ho, Cindy Zen, and Tan Kwee Lan of Boehringer Ingelheim give an overview of the current regulatory framework for…
See our Cookie Privacy Policy Here
